Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma

NCT ID: NCT07270835

Last Updated: 2025-12-08

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE4
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-11-01
• Study Completion Date: 2027-08-31

Brief Summary

For patients who met the inclusion criteria, treatment regimens were administered: Rituximab 375 mg/m², intravenously, once weekly for 4 weeks.

Zanubrutinib 160 mg, orally, twice daily for 4 weeks. Combined drugs: prednisone 100 mg/m²/d, orally, d1-5; Ruxolitinib 15mg bid orally; With/without emapalumab as appropriate.

Detailed Description

For patients who met the inclusion criteria, treatment regimens were administered:

Rituximab 375 mg/m², intravenously, once weekly for 4 weeks (may be extended or adjusted according to clinical response).

Zanubrutinib: 160 mg, orally, twice daily for 4 weeks as for rutuximab. Dose can be adjusted or extended according to tolerance and efficacy.

When ≥3 grade hematological or intolerable non-hematological toxicity occur, zanubrutinib or rituximab will be suspended, and the dose will be reduced or resumed according to the toxicity grade after recovery. The dose of zanubrutinib should be adjusted according to the manufacturer's label with concomitant use of strong CYP3A inhibitor/inducer.

Combined drugs: prednisone 100 mg/m²/d, orally, d1-5; Ruxolitinib 15mg bid orally; With/without emapalumab as appropriate.

Conditions

Hemophagocytic Lymphohistiocytosis; B Cell Lymphoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

intervention group

Rituximab 375 mg/m², intravenously, once weekly for 4 weeks (may be extended or adjusted according to clinical response).

Zanubrutinib: 160 mg, orally, twice daily for 4 weeks as for rutuximab. Dose can be adjusted or extended according to tolerance and efficacy.

When ≥3 grade hematological or intolerable non-hematological toxicity occur, zanubrutinib or rituximab will be suspended, and the dose will be reduced or resumed according to the toxicity grade after recovery. The dose of zanubrutinib should be adjusted according to the manufacturer's label with concomitant use of strong CYP3A inhibitor/inducer.

Combined drugs: prednisone 100 mg/m²/d, orally, d1-5; Ruxolitinib 15mg bid orally; With/without emapalumab as appropriate.

Group Type: EXPERIMENTAL

Rituximab

Intervention Type: DRUG

375 mg/m², intravenously, once weekly for 4 weeks

Zanubrutinib

Intervention Type: DRUG

160 mg, orally, twice daily for 4 weeks as for rutuximab.

Interventions

Rituximab

375 mg/m², intravenously, once weekly for 4 weeks

Intervention Type: DRUG

Zanubrutinib

160 mg, orally, twice daily for 4 weeks as for rutuximab.

Intervention Type: DRUG

Other Intervention Names

HALPRYZA; Brukinsa

Eligibility Criteria

Inclusion Criteria

• According to the diagnostic criteria of HLH-04, the patients meet the diagnostic criteria of HLH;
• HLH patients with definite or highly suspected evidence of B-cell lymphoma; Or HLH patients whose bone marrow flow cytometry show an increased proportion of CD20-positive B cells;
• Age of 14-80 years old, both sexes;
• Predicted survival beyond 1 month;
• Baseline serum creatinine ≤1.5 times ULN; Fibrinogen could be corrected to ≥0.6g/L by infusion;
• Negative serum HIV antibody; Either negative for HCV antibodies or positive for HCV antibodies but negative for HCV RNA. HBV surface antigen and HBV core antibody were negative. If any of the above was positive, HBV DNA titer in peripheral blood should be tested, and the titer was less than 1×10^3 copies /ml;
• Left ventricular ejection fraction (LVEF) ≥50% measured by echocardiography;
• The patient have no serious and uncontrollable infections, such as pulmonary infection, intestinal infection, and sepsis;
• Women of childbearing age must be confirmed to be not pregnant by pregnancy test and willing to take effective measures to prevent pregnancy during the study period and ≥12 months after the last dose; Pregnant and lactating women cannot participate; All male subjects took contraceptive measures during the trial and ≥3 months after the last dose;
• Patients should be able to sign informed consent.

Exclusion Criteria

• Patients with known severe allergy to rituximab, zanubrutinib, or other BTK inhibitors;
• Severe active infections (including bacterial, viral or fungal infections) or uncontrolled co-infections;
• Severe organ dysfunction including NYHA class III-IV heart failure or severe arrhythmia; Liver function: ALT or AST >5 times the upper limit, or severe cirrhosis; Renal function: CrCl <30 mL/min or severe renal insufficiency;
• Combined with other malignant tumors and the expected survival time was less than 3 months;
• Have received other experimental drugs and had not completed the drug washout period;
• Pregnant or lactating women, or unwilling to use effective contraception;
• any condition that would not be suitable for participation in the study or that might affect adherence, follow-up, or safety assessment, as judged by the investigator.

• Minimum Eligible Age: 14 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

The First Affiliated Hospital of Soochow University

OTHER

Sponsor Role: lead

Responsible Party

Xuefeng He

professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Xuefeng He, doctor

Role: PRINCIPAL_INVESTIGATOR

department of hematology, The First Affiliated Hospital of Soochow University

Locations

The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China

Site Status: RECRUITING

Countries

China

Central Contacts

Xuefeng He, doctor

Role: CONTACT

hexuefeng@suda.edu.cn

86-18914031640

Fei Zhou, doctor

Role: CONTACT

zhoufei@suda.edu.cn

86-15051425673

Facility Contacts

Xuefeng He, doctor

Role: primary

hexuefeng@suda.edu.cn

Fei Zhou, doctor

Role: backup

zhoufei@suda.edu.cn

Other Identifiers

HLH-003

Identifier Type: -

Identifier Source: org_study_id